ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2049 entries already.
Just one week to go until SLAS Europe 2025 takes place in Hamburg from 20–22 May. Organized by the Society for Laboratory Automation and Screening (SLAS), the premier automation conference in Europe will showcase the latest technologies and drug discovery enablers. As part of its preview series, European Biotechnology Magazine profiles 12 of Europe’s most innovative AveNew SMEs – this edition features UK-based Unicorn Biotechnologies.
On May 12, 2025, President Donald Trump signed an executive order aiming to drastically reduce U.S. prescription drug prices by aligning them with the lowest prices paid in other developed nations—a policy known as the “Most Favored Nation” (MFN) approach. While the initiative seeks to alleviate the financial burden on American patients, it has sparked intense debate over its potential ramifications on global pharmaceutical trade, investment patterns, and the United States’ leadership in biomedical innovation.
Belgian lysosomal storage disease specialist Azafaros BV has added a new lead investor to its portfolio. In addition to €25m Series A leader Forbion, Jeito Captial co-led a €132m Series B round aimed at advancing two pivotal trials of Azafaros‘ lead compound nizabagloustat (AZ-3102).
With only one week remaining until Europe’s largest event focused on laboratory automation and drug screening, preparations for SLAS Europe 2025 are well under way. Organised by the Society for Laboratory Automation and Screening (SLAS), the conference will be held in Hamburg from 20–22 May. As part of a dedicated series, European Biotechnology Magazine is highlighting twelve of the most innovative SMEs currently operating in the sector. Among them is Switzerland’s ORYL Photonics SA.
British cell and gene therapy CDMO eXmoor Pharma plc, and KU Leuven which has just launched a translational cell and gene therapy hub in Belgium have inked a strategic collaboration supporting the hub’s work in four areas.
Scientists at German Helmholtz Centre Munich have presented a new transport system for gene and cell therapy that overcomes the limitations of viral vectors. An in vivo gene therapy for hereditary blindness corrected the defect in the Rpe65 gene ten times more efficiently than was possible with viral vectors.
The Society of Laboratory Automation and Screening (SLAS) has named the five finalists for the SLAS Europe Poster Award, New Product Award and the SLAS Ignite Award that will be honored in Hamburg on 21 and 22 May, 2025.
Only three weeks to go until Europe’s largest event for laboratory automation and drug screening. SLAS Europe 2025, organised by the Society for Laboratory Automation and Screening (SLAS), will take place in Hamburg from 20-22 May. In a series, European Biotechnology Magazine presents the 12 most innovative SMEs today: Phabioc GmbH.
Building on the January 2025 ALS drug discovery collaboration with Alchemab Therapeutics, Eli Lilly & Company has secured rights to the first IND-ready program under a US$415m licensing agreement.
Only three weeks to go until Europe’s largest event for laboratory automation and drug screening. SLAS Europe 2025, organised by the Society for Laboratory Automation and Screening (SLAS), will take place in Hamburg from 20-22 May. In a series, European Biotechnology Magazine presents the 12 most innovative SMEs today: German HIPS spin-out Myxotech GmbH.